ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

8/9/22 8:32:38 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CCXI alert in real time by email

ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx.

ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, on August 8, 2022.

Get the next $CCXI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CCXI

Date	Price Target	Rating	Analyst
8/4/2022	$81.00	Buy	Canaccord Genuity
11/10/2021	$107.00 → $110.00	Strong Buy	Raymond James
10/11/2021	$14.00 → $38.00	Underweight → Neutral	JP Morgan
10/11/2021	$64.00	Mkt Perform → Outperform	SVB Leerink
10/11/2021	$62.00 → $107.00	Outperform → Strong Buy	Raymond James
10/8/2021	$62.00 → $107.00	Outperform → Strong Buy	Raymond James
10/8/2021		Neutral → Overweight	Piper Sandler
7/7/2021	$26.00 → $31.00	Hold → Buy	Stifel

More analyst ratings

$CCXI
Press Releases

Fastest customizable press release news feed in the world

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ:CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. "ChemoCentryx enhances Amgen's leading inflammation and nephrology portfolio and includes TAVNEOS® (avacopan), a first-in-cl
10/20/22 9:05:00 AM ET
$AMGN
$CCXI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephrology (ASN) Kidney Week 2022 and American College of Rheumatology (ACR) Convergence 2022 annual meetings taking place in November. American Society of Nephrology Kidney Week 2022, November 3-6, Orlan
10/17/22 8:30:00 AM ET
$CCXI
Biotechnology: Pharmaceutical Preparations
Health Care
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced two upcoming poster presentations for CCX559, the Company's investigational, highly potent, orally administered PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston, MA. ChemoCentryx Poster Presentations at SITC 37th Annual Meeting (November 8-12, 2022): Results From an Ongoing Open-Label, Multicenter, Phase 1 Trial of
10/5/22 8:30:00 AM ET
$CCXI
Biotechnology: Pharmaceutical Preparations
Health Care

$CCXI
Financials

Live finance-specific insights

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ:CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. "ChemoCentryx enhances Amgen's leading inflammation and nephrology portfolio and includes TAVNEOS® (avacopan), a first-in-cl
10/20/22 9:05:00 AM ET
$AMGN
$CCXI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx. ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, on August 8, 2022. About ChemoCentryx ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer.
8/9/22 8:30:00 AM ET
$CCXI
Biotechnology: Pharmaceutical Preparations
Health Care
ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307-1963 (International). The conference ID number is 9726781. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast wil
8/2/22 4:05:00 PM ET
$CCXI
Biotechnology: Pharmaceutical Preparations
Health Care

$CCXI
Leadership Updates

Live Leadership Updates

ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director
SAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board increases the number of directors constituting the whole Board from eight to nine. "With more than 25 years developing and refining her therapeutics commercial expertise, Jennifer is uniquely positioned to add immediate value to our TAVNEOS® (avacopan) commercial efforts," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "Jennifer's values closely align with our organization, and we are confident this addition
7/5/22 8:30:00 AM ET
$CCXI
Biotechnology: Pharmaceutical Preparations
Health Care
ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer
Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product SAN CARLOS, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this role, she will oversee development activities including clinical development, development operations, regulatory affairs, and drug safety and pharmacovigilance. Dr. Jain will continue to serve on the ChemoCentryx board of directors (where she has served since March of 2019) as an executive employee director. Dr. Jain, a board-certified rheumatologist, brings more than 20 years of drug de
10/11/21 8:30:00 AM ET
$CCXI
Biotechnology: Pharmaceutical Preparations
Health Care
ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors
MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021. “Susan Kanaya’s many fundamental contributions have been key to ChemoCentryx’s growth and prosperity,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Over many formative years of our enterprise, she ensured our strong financial position, allowing us to achieve our operational plans and thus increasing shareholder value while serving patients’ needs. As a
3/8/21 8:30:00 AM ET
$CCXI
Biotechnology: Pharmaceutical Preparations
Health Care

$CCXI
Market Insights

Live Market Insights

ChemoCentryx's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q2, ChemoCentryx's (NASDAQ:CCXI) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million. ChemoCentryx collected $5.46 million in revenue during Q1, but reported earnings showed a $38.61 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future.
9/1/22 10:20:27 AM ET
$CCXI
Biotechnology: Pharmaceutical Preparations
Health Care
Why Jim Cramer Says This Financial Stock Is 'Terrific'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Charles Schwab Corporation (NYSE:SCHW) is "terrific." Cramer said he prefers International Flavors & Fragrances Inc. (NYSE:IFF) over Amyris Inc (NASDAQ:AMRS) as the former is doing a "better job." When asked about Canopy Growth Corp (NASDAQ:CGC), Cramer said, "If Canopy Growth is good, then that means that you have one more reason to buy Constellation Brands, Inc. (NYSE:STZ)." The "Mad Money" host said he needs to do some more research on ChemoCentryx Inc (NASDAQ:CCXI). Cramer said he likes TechnipFMC PLC (NYSE:FTI) very, very much. He recommended waiting for a "couple day pullback." When asked about Ardagh Metal Packaging S.
8/12/22 8:07:32 AM ET
$AMBP
$AMRS
$BAC
$BALL
Containers/Packaging
Industrials
Major Chemicals
Major Banks
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
Upgrades According to Stifel, the prior rating for V2X Inc (NYSE:VVX) was changed from Hold to Buy. The current stock performance of V2X shows a 52-week-high of $33.69 and a 52-week-low of $29.55. Moreover, at the end of the last trading period, the closing price was at $29.81. Stifel upgraded the previous rating for Linde PLC (NYSE:LIN) from Hold to Buy. For the second quarter, Linde had an EPS of $3.10, compared to year-ago quarter EPS of $2.70. The stock has a 52-week-high of $352.18 and a 52-week-low of $265.12. At the end of the last trading period, Linde closed at $300.67. Barclays upgraded the previous rating for CF Industries Holdings Inc (NYSE:CF) from Equal-Weight to Overwe
8/10/22 10:11:54 AM ET
$ALLO
$AMRS
$APRN
$ARCT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Major Chemicals
Industrials

ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

Chat with this insight

Recent Analyst Ratings for $CCXI

$CCXI Press Releases

Fastest customizable press release news feed in the world

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

$CCXI Financials

Live finance-specific insights

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX